annual meeting program - American Society of Clinical Oncology

Saturday, June 5, 2010
Brd. 2C Breast conservation (BCT) for DCIS: A prospective study of how MRI impacts
management (MGMT). (Abstract #546)
J. L. Marti, J. I. Goldberg, S. Patil, V. V. Barbashina, D. D. Giri, S. Brennan, C. Lee,
C. Vallejo, E. A. Morris, K. J. Van Zee
Brd. 2D Trastuzumab versus observation in women with early breast cancer and
CK-19 mRNA-positive circulating tumor cells (CTCs): A pilot randomized
phase II study. (Abstract #547)
V. Georgoulias, V. Bozionelou, S. Agelaki, M. Perraki, S. Apostolaki, G. Kallergi,
K. Kalbakis, N. E. Androulakis, A. Xyrafas, D. Mavroudis
Brd. 2E The effect of different sequencing regimens of taxanes and anthracyclines in
the primary systemic treatment (PST) of breast cancer (BC) patients (pts):
M. D. Anderson Cancer Center retrospective analysis. (Abstract #548)
R. H. Alvarez, G. Bianchini, L. Hsu, M. Cristofanilli, F. J. Esteva, L. Pusztai,
A. Buzdar, G. N. Hortobagyi, V. Valero
Brd. 2F Phase II trial of preoperative vinorelbine/trastuzumab (VH) or
docetaxel/carboplatin/trastuzumab (TCH) in HER2-positive breast cancer
with analysis of resistance mechanisms. (Abstract #549)
I. E. Krop, L. Flores, D. P. Tuck, P. D. Ryan, A. H. Partridge, D. Morganstern,
J. Najita, K. lezon-Geyda, E. P. Winer, L. Harris
Brd. 2G Use of myxovirus resistance 1 (MX1) expression to predict efficacy of
anthracyclines-based chemotherapy: Biomarker studies from neoadjuvant
and adjuvant trials. (Abstract #550)
F. Andre, M. Delorenzi, A. Goubar, M. Lacroix, C. Desmedt, V. Scott, C. Sotiriou,
M. Mathieu, S. Delaloge, L. Pusztai
Brd. 2H Use of serum SDF-1 as a predictive biomarker for outcomes in the NCIC CTG
MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast
cancer. (Abstract #551)
M. Basik, A. Aguilar-Mahecha, J. W. Chapman, K. Jahan, S. Hassan, L. Han,
C. F. Wilson, K. I. Pritchard, L. E. Shepherd, M. N. Pollak
Brd. 3A Final analysis of a safety and efficacy trial of preoperative sequential
chemoradiation therapy for the nonsurgical treatment (NST) in early breast
cancer (EBC): Japan Clinical Oncology Group Trial (JCOG0306). (Abstract
#552)
H. Mukai, T. Watanabe, M. Mitsumori, H. Tsuda, S. Nakamura, N. Masuda,
N. Yamamoto, T. Shibata, A. Sato, K. Aogi
Brd. 3B Preoperative diagnosis of sentinel lymph node (SLN) metastasis using 3D CT
lymphography (CTLG): A new technology for sentinel node navigation.
(Abstract #553)
M. Nakagawa, M. Morimoto, T. Nagao, Y. Nakagawa Sr., A. Tangoku
Brd. 3C Report of toxicities from the multicenter, randomized NNBC 3-Europe trial:
6xFEC versus 3xFEC-3xDoc for high-risk node-negative breast cancer
patients. (Abstract #554)
C. Thomssen, E. J. Kantelhardt, K. Plueckhahn, C. Veyret, D. Augustin, V. Hanf,
D. Paepke, C. Meisner, G. Von Minckwitz, N. Harbeck, on behalf of the NNBC-3
Europe Study Group
Brd. 3D The role of beta-blockers and ACE inhibitors in the prevention of
trastuzumab-related cardiotoxicity. (Abstract #555)
J. Munoz, J. Sheqwara, B. Arango, H. Y. Ali, R. Loutfi, D. W. Weaver
Brd. 3E Predictive response factors (PRF) in an open, nonrandomized, phase II study
of a combination of bevacizumab (BZ) and sequential chemotherapy as
preoperative treatment in patients with operable HER2-negative breast
cancer (BC). (Abstract #556)
P. Sanchez Rovira, J. De la Haba, M. Fernández-Navarro, M. Seguí, A. Llombart-
Cussac, A. Anton, E. Alba, E. Aranda
147
SATURDAY